Accompanying therapies for tumour patients

Many patient owners and veterinarians are looking for additional therapies that can be used in addition to treatment with dendritic cells. There are numerous therapeutic approaches, including the interaction of immunology with surgery, radiation treatment and other therapies. Please ask us about the use of additional therapeutic options during an immunologic treatment cycle.

Treatment with dendritic cell therapy can be supported or accompanied by various treatment options:

• Support through other drugs to treat the occasional side effects and to pursue supportive/accompanying treatment methods:
  • Antibiotics (fluoroquinole), (short-term) corticoids (e.g. in lymphoma treatment, analgesics (e.g. metamizole or meloxicam), infusions, etc.)
• Radiotherapy: In the case of many tumours, e.g. skin and oral cavity tumours, radiation can be used as an additional therapeutic measure.
• Chemotherapy: There are currently no results available for the combination of dendritic cell therapy with chemotherapy. Studies are ongoing. We know from human medicine that both forms of therapy can be well combined. For example, dendritic cell therapy can be used after chemotherapy to support the onset of an increase in the number of leukocytes. Resistance to a chemotherapy protocol is reduced.
• Ozone therapy can be used together with DC therapy.
• Tyrosine kinase inhibitors are used together with DC therapy in human tumor patients. The tyrosine kinase inhibitors Palladia® and Masivet®) are used in veterinary medicine.
• Paramunization (Zylexis®) can be used before DC therapy and about 4 days after DC therapy.
• Naturopathic procedures such as acupuncture, homeopathy or homotoxicology, Sanum-Kehlbeck products (Sanukehl, Vetokehl) can be used safely together with DC treatments.
• Hyperthermia: If there is a possibility of hyperthermic treatment, the therapy should be performed the day before the DC treatment.
• Interferons have been used as danger signals in DC therapy. In the process, alpha- and beta-interferons are used in humans. The commercially available omega interferon for veterinary medicine has not yet been tested in connection with DC therapy. It can be assumed that even very small amounts of interferon could achieve a clearly positive additional effect in the treatment of tumours with dendritic cells.
• Nutrition: The nutrition of the patient should be analysed and individually adapted to the tumour disease and other living conditions of the animal. Nutrition has a major influence on the patient's metabolism and thus on the stability of the immune system.